Adicet Bio, Inc. Common Stock

ACETNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
7.26 USD
↘ 0.89 (10.92%)AT CLOSE (11:59 AM EDT)
7.24
↘ 0.02 (0.28%)
POST MARKET (AS OF 07:51 PM EDT)
Post Market
AS OF 07:51 PM EDT
7.24
↘ 0.02 (0.28%)
🔴Market: CLOSED
Open?$8.05
High?$8.06
Low?$7.26
Prev. Close?$8.15
Volume?86.6K
Avg. Volume?103.8K
VWAP?$7.57
Rel. Volume?0.83x
Bid / Ask
Bid?$6.14 × 100
Ask?$8.76 × 100
Spread?$2.62
Midpoint?$7.45
Valuation & Ratios
Market Cap?67.9M
Shares Out?9.3M
Float?8.2M
Float %?85.2%
P/E Ratio?N/A
P/B Ratio?0.48
EPS?-$11.64
Dividend?0.00%
Ex-Dividend?N/A

Shares of Adicet Bio, Inc. Common Stock (ACET) are trading at $7.26. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, ACET appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 5, 2026.

RelatedADMA
News
Profile
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Cell & Gene Therapy for Cancer
Employees
102
Market Cap
67.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.adicetbio.com
Listed
2020-09-16
Address
131 DARTMOUTH STREET
BOSTON, MA 02116
Phone: 617-482-2333
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
55
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.21Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?7.20%Elevated
Short Interest?587.8K
Days to Cover?5.7
Free Float8.2M
Avg Daily Volume103.5K
Settlement Date2026-05-15
Financial Health
Current Ratio?7.65Strong
Quick Ratio?7.65Strong
Cash Ratio?1.98Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.48CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-0.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
Peers
50
S&P
3
-77.7%WEAK▾
ROA?
Peers
50
S&P
3
-64.3%WEAK▾
Cash Flow & Enterprise
FCF?$-91622000
Enterprise Value?$32.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist